Advancing End-to-End Continuous Manufacturing for Biologics & Biosimilars
Time: 12:00 pm
day: Day One Track B AM
Details:
- CM implementation hurdles when moving from development to phase III manufacturing
- Regulatory assessment of CM
- CoGs is the driver for CM of Biosimilars & Biologics
